Does evolocumab reduce LDL cholesterol levels in pediatric patients with heterozygous familial hypercholesterolemia?
Evolocumab effectively reduces LDL cholesterol in pediatric patients with heterozygous familial hypercholesterolemia.
In this trial involving pediatric patients with familial hypercholesterolemia, evolocumab reduced the LDL cholesterol level and other lipid variables. (Funded by Amgen; HAUSER-RCT ClinicalTrials.gov number, NCT02392559.).
Santos et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: